Hématologie clinique - Pitié-Salpêtrière Hospital (APHP)
Paris, 75013, France
Location contact
Anne LE BORGNE, Mrs
CONTACT
01 84 82 83 15 ext. + 33
Laurent Dr GARDERET, MD
CONTACT
01 42 16 27 94 ext. + 33
NCT Number: NCT07276230
The diagnosis and treatment of multiple myeloma affect not only the patient but also their family and caregivers. Advances in therapy have transformed the follow-up of patients treated for multiple myeloma. The involvement of informal caregivers has become increasingly essential to ensure adequate home-based care, as most treatments are now delivered on an outpatient basis. Literature reviews suggest that caregivers of cancer patients often face unmet supportive care needs, which in turn negatively impact their quality of life.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Paris, 75013, France
Anne LE BORGNE, Mrs
CONTACT
01 84 82 83 15 ext. + 33
Laurent Dr GARDERET, MD
CONTACT
01 42 16 27 94 ext. + 33
By improving the quality of life of caregivers, the intervention can help prevent cascading effects such as a deterioration in the quality of life of the care recipient, thereby reducing the overall burden on healthcare systems. In addition, therapeutic education is an ongoing process aimed at helping patients and/or caregivers acquire or maintain the skills they need to best manage their lives with a chronic condition.
Study procedures :
The Shared Educational Assessment is a discussion between the healthcare professional and the caregiver focusing on the skills to be acquired or strengthened in order to improve health and quality of life. It enables exploration and assessment of the caregiver's needs and resources in terms of :
The topics addressed in the workshops are as follows:
The questionnaire will be available in paper format, and the responses will be entered into an electronic case report form (e-CRF) using the CleanWeb system. The data will be analyzed by the Clinical Research Unit (URC).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Caregiver :
Exclusion criteria
Caregiver :
Participation in a weekly therapeutic education group for 4 weeks.
Time frame: 3 months
Change in caregivers' CarGOQoL (CareGiver Oncology Quality of Life) scores between baseline and 3 months. The higher the score, the better the quality of life.
Time frame: 3 months
Proportion of caregivers who completed the entire therapeutic education program
Time frame: 6 months
Assessment of self-care and coping skills using a four-level competency acquisition scale: acquired, not acquired, introduced, and reinforcement session required
Time frame: 2 weeks
Caregivers' satisfaction measured using a Visual Analogue Scale (VAS) ranging from 1 to 10. The higher the score, the greater the satisfaction.
Time frame: 6 months
Change in caregivers' CarGOQoL (CareGiver Oncology Quality of Life) scores between baseline and 6 months. The higher the score, the better the quality of life.
Contact information is provided by the study sponsor or research team.
Anne LE BORGNE, Mrs
CONTACT
01 84 82 83 15 ext. + 33
Laurent Dr GARDERET, MD
CONTACT
01 42 16 27 94 ext. + 33
Assistance Publique - Hôpitaux de Paris
Other
Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma Participating in a Therapeutic Education Program and Receiving a Supportive Care Needs Evaluation
Acronym: ENTRAIDANT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07742527
Blood Protein Disorders, Cardiovascular Diseases
View Trial DetailsNCT07740317
Blood Protein Disorders, CART Therapy
Charlotte, North Carolina, United States
View Trial DetailsNCT07740486
Blood Protein Disorders, Cardiovascular Diseases
View Trial DetailsNCT07735546
Blood Protein Disorders, Cardiovascular Diseases
View Trial Details